

## Genovis Interim Report January – September 2015

### Summary: third quarter 2015

- Net sales increased by 105% to SEK 3,358k (1,639k).
- Gross profit improved by SEK 3,084 to SEK 822k (-2,262k).
- Loss after tax worsened to SEK 6,647k (loss: 5,545k). Non-recurring expenses had a negative impact on earnings of SEK 4,888k. Excluding non-recurring expenses, the result is better than last year.
- Comprehensive income was a loss of SEK 6,470k (loss: 5,545k).
- Comprehensive income per share totaled SEK -0.18 (-0.25).
- Cash flow from operating activities was SEK -2,698k (-4,537k).
- Cash and cash equivalents including short-term investments amounted to SEK 6,145k (12,003k) at the end of the period.
- Genovis reorganized, discontinued operations in the subsidiary GeccoDots and sold the intellectual property rights behind the Nanomotus project to the inventors against future royalties.

### Summary of the first nine months of 2015

- Net sales rose by about 59% to SEK 9,770k (6,153k).
- Gross profit/loss improved by SEK 2,590 to SEK -1,293k (-3,883k).
- Loss after tax worsened to SEK 16,844k (loss: 14,187k). Non-recurring expenses had a negative impact on earnings of SEK 6,036k. Excluding non-recurring expenses, the result is better than last year.
- Comprehensive income was a loss of SEK 16,825k (loss: 14,187k).
- Comprehensive income per share totaled SEK -0.61 (-0.66).
- Cash flow from operating activities was SEK -12,177k (-16,515k).

## Financial overview

	July – September		January–September		Jan.-Dec.
	2015	2014	2015	2014	2014
Net sales	3,358	1,639	9,770	6,153	8,252
Other operating income	3,374	579	5,224	1,419	1,782
Expenses for the period	(13,124)	(7,804)	(31,646)	21,877	(30,505)
Gross profit/loss	822	(2,262)	(1,293)	(3,883)	5,979
EBITDA	(2,330)	(5,276)	(11,918)	(13,416)	(19,197)
Operating profit/loss	(6,392)	(5,586)	(16,652)	(14,305)	(20,471)
Comprehensive income for the period	(6,470)	(5,545)	(16,652)	(14,187)	(22,049)
Comprehensive income per share based on a weighted average of the number of outstanding shares	(0.18)	(0.25)	(0.61)	(0.66)	(1.02)
Cash flow from operating activities	(2,698)	(4,537)	(12,177)	(16,516)	(22,193)
Cash and cash equivalents, including short-term investments at end of period	6,145	12,003	6,145	12,003	5,688

\* Includes non-recurrent expenses of SEK 4,888k for July-Sept. and SEK 6,036k for Jan.-Jan.-Sept.

## Comments from CEO Fredrik Olsson

It is extremely satisfying to note that we more than doubled our sales in the third quarter compared with the same period last year. So far this year, sales have increased by almost 60 percent and for the first time in years, we can report a positive gross profit. Cash flow also improved substantially in the third quarter compared with previous quarters this year and the same period last year.

Operating earnings before depreciation (EBITDA) improved by almost SEK 3 million compared with the corresponding period last year. Even compared with the first and second quarters of this year, the improvement in earnings in the third quarter is significant.

Operations in GeccoDots were discontinued in the third quarter and we have divested parts of the company's intellectual property rights to the inventors against future royalties. By discontinuing operations at GeccoDots we will also reduce costs moving forward, primarily relating to patent and personnel costs. Although some restructuring costs were already taken in the second quarter, most are charged to the current quarter. In connection with the restructuring, we also decided to write down all intangible assets in GeccoDots, which has a negative impact on earnings. In total, restructuring costs for the third quarter amounted to SEK 4.9 million; excluding these costs, third quarter results improved significantly compared with previous quarters this year and clearly demonstrate our commitment to move toward a profitable business.

Genovis' product portfolio consists of two types of enzymes, proteases and glycosidases. The market for proteases for use throughout the life science area is approximately USD 100 million annually. All proteases that Genovis introduced in this market since 2010 currently account for about 2 percent of the market, and we intend to further increase our market share moving forward. Since its inception, Genovis has built on the idea that a good business is based on delivering a unique product that has a high value for the customer. Genovis has also chosen a path that has not been trodden before, and our philosophy for achieving high value is that it is necessary to go

where others have not gone before. The products launched earlier this year continue to grow beyond expectations and thereby contribute to reducing Genovis' dependence on individual products. The products we will launch in the future will also be unique and solve important problems for our customers.

We can conclude that the third quarter confirms that we are improving our business through close relationships with our customers. Solving our customers' problems and challenges with unique products will drive our sales even further. We will therefore continue to prioritize sales and marketing with the launch of new products.

In addition, the number of scientific publications in which our enzymes were used almost doubled this year compared with last year, yet another confirmation of the uniqueness and relevance of our products to our customers. I am extremely pleased and proud of all employees at Genovis who contribute their energy and creativity every day to find new and more effective solutions to our customers' problems.

## Genovis' Products

FabRICATOR<sup>®</sup> (IdeS), FabRICATOR<sup>®</sup>Z (IdeZ), GingisKHAN<sup>™</sup> (KGP), FabULOUS<sup>®</sup> (SpeB)  
IgGZERO<sup>®</sup> (EndoS), GlycINATOR<sup>®</sup> (EndoS2)

FabRICATOR is a unique enzyme that cleaves antibodies into two parts: a Fab fragment and an Fc fragment, with extremely high precision and FabRICATOR<sup>®</sup>Z also cleaves a specific type of mouse IgG quickly and more effectively than FabRICATOR and the other enzymes on the market. FabULOUS is an enzyme that cleaves an antibody into three parts. The product is a complement to FabRICATOR. By using the two products together, the customer gets a fast method to characterize the "hinge region" of an antibody, which is important in many antibody drug conjugate (ADC) drug candidates. IgGZERO is a protein that can specifically cleave sugar molecules that are found naturally on antibodies for "glycan analysis." GlycINATOR is another enzyme that can rapidly cleave sugar molecules from an antibody. By using IgGZERO in combination with GlycINATOR it is possible to carry out a relatively simple quantitative analysis of high-mannose molecules on antibodies. Mannose is a particularly important parameter to understand and handle when developing production processes for antibody-based drugs. GingisKHAN<sup>™</sup> is an enzyme that cleaves human antibodies into three parts. The product complements FabRICATOR<sup>®</sup> and FabULOUS<sup>®</sup>, but can also be used in studies of the different parts of the antibody separately, which makes the product unique.

Customers use the products in recurring processes. In addition to the actual product, Genovis provides global deliveries and support within 24 hours. During product development, Genovis places great emphasis on ensuring that the customer experience is as positive as possible, which means that the products must be robust, easy to use and stable during shipping and storage. Standardized formats, clear instructions and close customer relationships are key elements to ensure that the product works as intended, even for inexperienced customers. The products can be ordered from a standard product line or adapted to the needs of the customer. Customers use the products to screen new drug substances and for quality control in development and production of new antibody-based drugs.

## Sales

### Net sales

Net sales for the period rose to SEK 9,770k (6,153k), an increase of 59% compared with the same period in 2014. Net sales for the third quarter rose to SEK 3,358k (1,639k), an increase of 105% compared with the same period in 2014.

### Other operating income

Other operating income during the period amounted to SEK 5,224k (1,419k) and during the third quarter SEK 3,374 (579k), and largely comprise insurance reimbursement in connection with the ongoing patent dispute in the US.

## Revenue by geographic area (SEK thousands)

	Jan.-Sept.		Jan.-Dec.
	2015	2014	2014
Europe	2,687	2,094	3,135
North America	6,716	3,902	4,841
Rest of world	367	157	276
<b>Total</b>	<b>9,770</b>	<b>6,153</b>	<b>8,252</b>

## Profit/loss

### Gross profit/loss

Consolidated gross loss for the period amounted to SEK 1,293k (loss: 3,883k). For the third quarter Genovis demonstrated a consolidated profit of SEK 822k (loss: 2,262k). Increased revenue for the Group as well as reduced costs resulting from the winding up of the subsidiary GeccoDots contributed to the improved performance.

### Financial income and expenses

Net financial expenses and income for the period amounted to SEK -33k (118k) and for the third quarter SEK -2k (41k).

### Profit/loss for the period

Consolidated profit/loss after tax for the period was SEK 16,844k (loss: 14,187k); the third quarter accounted for a loss of SEK 6,647k (loss: 5,545k). Non-recurrent expenses of SEK 6 million resulting from the winding up of the subsidiary GeccoDots had a negative impact on the result for the period, of which SEK 4.9 million had a negative impact on the third quarter. Excluding non-recurring expenses, the result is better than last year for both the period and the third quarter.

Comprehensive income for the period was a loss of SEK 16,825k (loss: 14,187k); the third quarter accounted for a loss of SEK 6,470k (loss: 5,545k)

## Expenses

Consolidated expenses for the period increased by SEK 9,769k to SEK 31,646k (21,877k). Operating expenses are allocated as follows: raw materials and consumables SEK 1,564k (2,659k) and other external expenses SEK 14,723k (8,796k). The increase in other external expenses is largely attributable to attorney fees in connection with the lawsuit against Promega, where the majority of expenses are covered by Genovis' insurance. Personnel costs totaled SEK 10,493k (9,498k), of which SEK 2,136k are non-recurrent expenses attributable to the restructuring and winding up of GeccoDots, which was completed in the third quarter.

Total expenses for the third quarter were SEK 13,124k (7,804k). Operating expenses are allocated as follows: raw materials and consumables SEK 150k (1,219k), other external expenses SEK 5,760k (3,261k) and personnel costs SEK 3,203k (3,002k).

## Investments

Consolidated capital expenditure during the period totaled SEK 1,533k (2,179k), of which SEK 109k (841k) is attributable to property, plant, and equipment, primarily laboratory equipment and computers, and SEK 1,424k (1,335k) is attributable to investments in intangible fixed assets. Consolidated capital expenditure during the third quarter totaled SEK 331k (289k), of which SEK 0 (13k) is attributable to property, plant, and equipment, and SEK 331k (276k) is attributable to investments in intangible fixed assets.

## Cash Flow

Consolidated cash flow for the period totaled SEK 5,457k (6,523k). Cash flow from financing activities totaled SEK 14,167k (27,218k) and is attributable to the rights issues in 2014 and 2015.

Cash flow for the third quarter was SEK -3,095k (2,674k). Cash flow from financing activities totaled SEK -65k (0).

## Financial position

Consolidated cash and cash equivalents including short-term investments amounted to SEK 6,145k (12,003k) at the end of the period.

The Board of Directors holds the opinion that the Group's current working capital is sufficient to run the Company over the next twelve months. In addition, the Annual General Meeting of May 5, 2015, authorized the Board to issue new shares if the Board considers the investment to be necessary to further increase sales.

The Company does not have any interest-bearing liabilities.

Total shareholders' equity for the Group was SEK 11,925k after taking the result for the period into account. Earnings per share for the period, based on a weighted average of the number of outstanding shares, totaled SEK -0.61 (-0.66), with SEK -0.18 (-0.25) for the third quarter. The Group's equity ratio at the end of the period was 67 percent (81 percent) and equity per share was SEK 0.43 (1.05), based on fully diluted shares at the end of the period.

## Taxes

The Group has a deferred tax asset that arises from the parent company, amounting to SEK 1,718k (3,436k) at the end of the period.

## Employees

On September 30, 2015, the Group had thirteen employees, compared with the same period the previous year, when the Group had sixteen employees. For both periods all employees were in the parent company.

## Share capital and Share Performance

Share capital at the end of the period amounted to SEK 9,215,693.75. The total number of shares was 36,862,775 with a par value of SEK 0.25. The Company has issued 450,000 warrants subscribed to by CEO Fredrik Olsson and Chairman of the Board Sarah Fredriksson.

Genovis shares are traded on NASDAQ First North Stockholm under the ticker symbol GENO. First North is an alternative market, operated by the various exchanges within NASDAQ OMX. Companies on First North are subject to the rules of First North and not the legal requirements for admission to trading on a regulated market. The Company's Certified Adviser is Consensus, tel: +46 (0)31-745 50 00.

## Parent Company

Net sales and operating profit/loss in the parent company are attributable to the primary and only business area: sales and/or outlicensing of research-based innovations. According to Genovis, the company does not meet the definition of geographical areas under IAS 14 and therefore no secondary segment information is provided.

### Revenue

Revenue for the period totaled SEK 14,537k (8,888k); SEK 7,854k (6,079k) was attributable to revenue from external sales and SEK 6,683k (2,809k) to other revenue. Revenue for the third quarter was SEK 6,155k (2,688k), of which SEK 2,562k (1,639k) was attributable to revenue from sales and SEK 3,593k (1,049k) to other revenue. Other revenue largely comprises insurance reimbursement in connection with the ongoing patent dispute in the US.

### Expenses

Total operating costs for the period amounted to SEK 29,300k (19,076k), including SEK 6,666k in one-off costs. Expenses for the third quarter were SEK 12,732k (6,428k), including SEK 5,518k in one-off costs. The non-recurrent expenses are related to increased personnel costs, impairment of patents and amortization of debt on the subsidiary as a result of the restructuring and liquidation of GeccoDots, which was completed during the third quarter.

In addition to non-recurrent expenses for restructuring, other external expenses are largely attributable to attorney fees in connection with the lawsuit against Promega, where the majority of expenses are covered by Genovis' insurance.

### Profit/loss

Operating loss for the period was SEK 14,763k (loss: 10,188k) and loss after net financial items was SEK 17,093k (loss: 14,170k). Adjusted for non-recurring costs of SEK 6,666k, the result is better than last year.

The operating loss for the third quarter was SEK 6,577k (loss: 3,740k) and loss after net financial items was SEK 6,577k (loss: 5,549k). Adjusted for non-recurring costs of SEK 5,518k, the result is better than last year.

A conditional shareholder contribution to the subsidiary of SEK 2,300k (4,100k) had a negative impact on the parent company's income statement. Net capital expenditure totaled SEK 705k (1,648k). Cash and cash equivalents including short-term investments totaled SEK 3,697k (11,669k) at the end of the period.

### Taxes

The parent company has a deferred tax asset that amounted to SEK 1,718k (3,436k) at the end of the period, equivalent to a loss carryforward of about SEK 7.8m, which is expected to be utilized in the foreseeable future. The Company's total tax loss amounts to SEK 129 million.

## Subsidiary GeccoDots AB

All activities of the subsidiary GeccoDots ended on September 30, 2015. All intangible and tangible assets have been transferred to the Parent Company, which decided to sell the intellectual property rights behind the Nanomotus project to the inventors against future royalties.

## Subsidiary Genovis Inc.

The subsidiary Genovis Inc. handles all sales and marketing in the North American market.

## Related party transactions

Genovis has purchased analysis services from Redeye for a total of SEK 322k. Genovis board member and principal owner Mikael Lönn, who holds a 22.15 percent stake in Genovis, owns 19.25 percent of the shares in Redeye, for which Mikael Lönn is also a board member.

## Events after the end of the period

No other events were reported after the end of the period.

## Outlook

Genovis has chosen not to issue any forecasts. Although the Life Science field is relatively independent of business cycles, periods of uncertainty can influence our customers' appetite to invest in new technology. With all development projects proceeding according to plan, Genovis is positioned to make additional advances with respect to both new products and sales.

## Risk factors

Genovis' general view of the financial risks that could affect operations has not changed since the description published in the most recent annual report. Genovis' business risks include the difficulties in retaining skilled personnel and the risk that anticipated revenue might not materialize since the Company is active in a market in which competing companies have substantially larger financial resources at their disposal. For a detailed overview of the Company's financial risks please refer to pages 50–51 in Genovis' 2014 annual report.

## Accounting policies

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the relevant provisions of the Swedish Annual Accounts Act. The interim report for the Parent Company has been prepared in accordance with chapter 9 of the Swedish Annual Accounts Act, Interim Reports. The accounting policies applied for the Group and the parent company are consistent with the accounting policies used in the preparation of the most recent annual report.



Consolidated statement of comprehensive income (SEK thousands)	July-Sept.		Jan.-Sept.		Jan.-Dec.
	2015	2014	2015	2014	2014
Net sales	3,358	1,639	9,770	6,153	8,252
Other operating income	3,374	579	5,224	1,419	1,782
Raw material and consumables	(150)	(1,219)	(1,564)	(2,659)	(3,430)
Other external expenses	(5,760)	(3,261)	(14,723)	(8,796)	(12,583)
<b>Gross profit/loss</b>	<b>822</b>	<b>(2,262)</b>	<b>(1,293)</b>	<b>(3,883)</b>	<b>(5,979)</b>
Personnel costs	(3,203)	(3,002)	(10,493)	(9,498)	(13,186)
Other operating expenses	51	(12)	(132)	(35)	(32)
<b>Operating loss before depreciation and amortization (EBITDA),</b>	<b>(2,330)</b>	<b>(5,276)</b>	<b>(11,918)</b>	<b>(13,416)</b>	<b>(19,197)</b>
Depreciation, amortization, and impairment losses of plant, property, and equipment and intangible assets	(4,062)	(310)	(4,734)	(889)	(1,274)
<b>Operating profit (EBIT)</b>	<b>(6,392)</b>	<b>(5,586)</b>	<b>(16,652)</b>	<b>(14,305)</b>	<b>(20,471)</b>
Net financial items	-2	41	(33)	118	140
<b>Loss after financial items</b>	<b>(6,394)</b>	<b>(5,545)</b>	<b>(16,685)</b>	<b>(14,187)</b>	<b>(20,331)</b>
Taxes	-73	0	(159)	0	(1,718)
<b>Net earnings</b>	<b>(6,467)</b>	<b>(5,545)</b>	<b>(16,844)</b>	<b>(14,187)</b>	<b>(22,049)</b>
Other comprehensive income	(3)	0	19	0	0
Comprehensive income for the period	<b>(6,470)</b>	<b>(5,545)</b>	<b>(16,825)</b>	<b>(14,187)</b>	<b>(22,049)</b>
Attributable to shareholders in Genovis AB	(6,470)	(5,545)	(16,825)	(14,187)	(22,049)

	July-Sept.		Jan.-Sept.		Jan.-Dec.
	2015	2014	2015	2014	2014
Earnings per share based on weighted average of the number of outstanding shares (basic and diluted)*.	(0.18)	(0.25)	(0.61)	(0.66)	(1.02)

Number of outstanding shares	July-Sept.		Jan.-Sept.		Jan.-Dec.
	2015	2014	2015	2014	2014
Weighted average for the period	36,816,930	21,845,652	27,789,523	21,435,588	21,538,104
Number of shares at beginning of period	36,409,420	21,845,652	21,845,652	15,780,757	15,780,757
Number of shares at end of period	36,862,775	21,845,652	36,862,775	21,845,652	21,845,652
Share price at end of period, SEK	1.87	3.55	1.87	3.55	1.92

\*The outstanding warrants do not entail any dilution of earnings per share since a conversion to shares would result in improved reported earnings per share.

Summary Consolidated Balance Sheet  
 (SEK thousands)

Sept. 30

2015                      2014

	2015	2014
<b>Assets</b>		
<i>Noncurrent assets</i>		
Intangible assets	2,687	5,109
Property, plant and equipment	1,854	2,152
Financial fixed assets	1,718	3,436
<i>Current assets</i>	5,418	5,090
Short-term investment	0	5,000
Cash and cash equivalents	6,145	7,003
<b>Total assets</b>	<b>17,822</b>	<b>27,790</b>

<b>Equity and liabilities</b>		
Equity	11,925	22,444
Non-current liabilities	180	0
Current liabilities	5,717	5,346
<b>Total equity and liabilities</b>	<b>17,822</b>	<b>27,790</b>

**Consolidated statement of changes in equity**  
 (SEK thousands)

Amount at start of period	14,583	33,085
New issue	14,167	3,547
Currency differential	19	0
Profit/loss for the period	(16,844)	(14,188)
<b>Amount at end of period</b>	<b>11,925</b>	<b>22,444</b>
Attributable to shareholders in Genovis AB	11,925	22,444

**Key financial ratios**

Equity/assets ratio	67%	81%
Equity per share at end of period	0.43	1.05

\* Based on weighted average of the number of outstanding shares (basic and diluted)\*.

## Summary Consolidated statement of cash flows

(SEK thousands)	July-Sept.		Jan.-Sept.		Jan.- Dec.
	2015	2014	2015	2014	2014
<b>Cash flow from operations</b>	<b>(6,392)</b>	<b>(5,587)</b>	<b>(16,652)</b>	<b>(14,305)</b>	<b>(20,471)</b>
Adjustment for items not affecting cash flow	4,061	310	4,753	890	1,274
Changes in working capital	(365)	699	(245)	(3,219)	(3,136)
Net financial items	-2	41	(33)	118	140
<b>Cash flow from operating activities</b>	<b>(2,698)</b>	<b>(4,537)</b>	<b>(12,177)</b>	<b>(16,516)</b>	<b>(22,193)</b>
Investing activities	(332)	7,211	3,467	(4,179)	(5,043)
<b>Cash flow after investing activities</b>	<b>(3,030)</b>	<b>2,674</b>	<b>(8,710)</b>	<b>(20,695)</b>	<b>(27,236)</b>
Financing activities	(65)	0	0	0	226
New issue	0	0	14,167	27,218	27,218
<b>Cash flow for the period</b>	<b>(3,095)</b>	<b>2,674</b>	<b>5,457</b>	<b>6,523</b>	<b>208</b>
Cash and cash equivalents at start of period	9,240	4,329	688	480	480
Cash and cash equivalents at close of period	<b>6,145</b>	<b>7,003</b>	<b>6,145</b>	<b>7,003</b>	<b>688</b>

## Parent Company

### Summary Income Statement

(SEK thousands)	July-Sept.		Jan.-Sept.		Jan.-Dec.
	2015	2014	2015	2014	2014
Operating income	6,155	2,688	14,537	8,888	12,005
Operating expenses	(12,732)	(6,428)	(29,300)	(19,076)	(26,848)
<b>Operating profit/loss</b>	<b>(6,577)</b>	<b>(3,740)</b>	<b>(14,763)</b>	<b>(10,188)</b>	<b>(14,843)</b>
Net financial items	0	(1,809)	(2,330)	(3,982)	(5,445)
<b>Profit/loss before tax</b>	<b>(6,577)</b>	<b>(5,549)</b>	<b>(17,093)</b>	<b>(14,170)</b>	<b>(20,288)</b>
Deferred tax on net loss for the period	0	0	0	0	(1,718)
<b>Profit/loss for the period</b>	<b>(6,577)</b>	<b>(5,549)</b>	<b>(17,093)</b>	<b>(14,170)</b>	<b>(22,006)</b>

### Summary Balance Sheet

(SEK thousands)	Sept. 30		Dec. 31
	2015	2014	2014
<b>Assets</b>			
Noncurrent assets	6,152	11,635	9,444
Current assets	6,861	4,460	4,014
Short-term investment	0	5,000	5,000
Cash and cash equivalents	3,697	6,669	614
<b>Total assets</b>	<b>16,710</b>	<b>27,764</b>	<b>19,072</b>

Equity and liabilities (SEK thousands)	Sept. 30		Dec. 31
	2015	2014	2014
<b>Equity</b>			
Restricted equity	15,056	20,756	20,756
Non-restricted equity	(3,404)	1,658	(6,178)
<b>Liabilities</b>			
Current liabilities	5,058	5,350	4,494
<b>Total equity and liabilities</b>	<b>16,710</b>	<b>27,764</b>	<b>19,072</b>

(SEK thousands)	Sept. 30		Dec. 31
	2015	2014	2014
Amount at start of period	14,578	33,037	33,037
New issue	14,167	3,547	3,547
Profit/loss for the period	(17,093)	(14,170)	(22,006)
<b>Amount at end of period</b>	<b>11,652</b>	<b>22,414</b>	<b>14,578</b>
Attributable to shareholders in Genovis AB	11,652	22,414	14,578

Summary statement of cash flows Jan-Dec. (SEK thousands)	July-Sept.		Jan.-Sept.		Jan.- Dec.
	2015	2014	2015	2014	2014
<b>Cash flow from operations</b>	<b>(6,577)</b>	<b>(3,740)</b>	<b>(14,763)</b>	<b>(10,188)</b>	<b>(14,843)</b>
Adjustment for items not affecting cash flow	4,638	279	5,208	800	1,085
Changes in working capital	(492)	1,088	998	(2,194)	(2,605)
Net financial items	0	41	(30)	117	155
<b>Cash flow from operating activities</b>	<b>(2,431)</b>	<b>(2,332)</b>	<b>(8,587)</b>	<b>(11,465)</b>	<b>(16,208)</b>
Investing activities	(1,974)	5,073	(2,497)	(9,455)	(10,767)
<b>Cash flow after investing activities</b>	<b>(4,405)</b>	<b>2,741</b>	<b>(11,084)</b>	<b>(20,920)</b>	<b>(26,975)</b>
Financing activities	(65)	0	14,167	27,218	27,218
<b>Cash flow for the period</b>	<b>(4,470)</b>	<b>2,741</b>	<b>3,083</b>	<b>6,298</b>	<b>243</b>
Cash and cash equivalents at start of period	8,167	3,928	614	371	371
Exchange rate difference in cash and cash equivalents	0	0	0	0	0
Cash and cash equivalents at close of period	<b>3,697</b>	<b>6,669</b>	<b>3,697</b>	<b>6,669</b>	<b>614</b>

Lund November 2, 2015

Genovis AB (publ.)

On behalf of the Board of Directors Fredrik Olsson, CEO

### Future reporting dates:

Year-end report	February 18
Interim Report January-March	May 4
Annual General Meeting	May 12

This interim report may be ordered from the Company or downloaded at the Genovis web site: [www.genovis.com](http://www.genovis.com).

Genovis AB, Box 790, SE-220 07 Lund, Sweden T: +46 (0)46-10 12 30, fax: +46 (0)46-12 80 20

For more information, please contact:

Fredrik Olsson, CEO

T: +46 (0)46-12 12 33

*This document is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.*

## Report of Review of Interim Financial Information

### Introduction

We have reviewed the condensed interim financial information (interim report) of Genovis AB (publ.) as of 30 September 2015 and the nine-month period then ended. The board of directors and the CEO are responsible for the preparation and presentation of the interim financial information in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

### Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, *Review of Interim Report Performed by the Independent Auditor of the Entity*. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing, ISA, and other generally accepted auditing standards in Sweden. The procedures performed in a review do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not prepared, in all material respects, in accordance with IAS 34 and the Swedish Annual Accounts Act, regarding the Group, and with the Swedish Annual Accounts Act, regarding the Parent Company.

Malmö, Sweden, November 2, 2015  
PricewaterhouseCoopers

Magnus Willfors  
Authorized Public Accountant

Sofia Götmar-Blomstedt  
Authorized Public Accountant